Iran has achieved a significant milestone in anticancer drugs production. An official from the country’s Food and Drug Administration (FDA) confirmed that 95 percent of anticancer drugs are now manufactured domestically. This development marks a major step toward strengthening the national pharmaceutical industry.
Akbar Abdollahiasl, Director General of the FDA for Pharmaceutical Affairs, recently provided these details. He emphasized the importance of local manufacturing in meeting the country’s healthcare needs. Furthermore, Abdollahiasl noted that while some patients and doctors still prefer foreign-brand medications, the government encourages the use of domestically produced drugs.
The Iranian government has implemented supportive policies to bolster local drug production. For example, these policies include restricting the import of certain foreign anticancer drugs when similar alternatives are available domestically. As a result, the country reduces dependency on imports and fosters national industry growth.
Iran’s focus on anticancer drugs production aligns with broader healthcare objectives. Specifically, the country seeks to ensure steady access to essential medications and improve affordability for patients. Moreover, producing 95 percent of these drugs internally reduces supply chain vulnerabilities and can lower costs.
This achievement did not happen overnight. Instead, Iran’s pharmaceutical sector has invested heavily in research, development, and manufacturing infrastructure. Consequently, domestic producers have expanded their capabilities to meet international standards. Their success demonstrates the capacity of the local industry to fulfill complex medical needs.
The FDA continues to monitor and support the sector through regulatory oversight and policy guidance. By encouraging innovation and quality control, officials aim to sustain and increase the share of local anticancer drugs production. Therefore, this strategy helps the country face external economic pressures.
Experts believe this trend will have positive social and economic impacts. For instance, it could lead to more job creation and improve healthcare outcomes for cancer patients nationwide. Additionally, domestic production may enhance Iran’s position in the regional pharmaceutical market.
Looking ahead, the government plans to maintain its support for pharmaceutical companies. Officials expect the share of locally produced anticancer drugs to rise even further. Thus, this commitment signals a long-term vision to make Iran self-sufficient in critical medicines.
In summary, Iran’s anticancer drugs production now covers 95 percent of national demand. Thanks to government policies and industry efforts, this has become possible. Consequently, the country is poised to strengthen its healthcare system and reduce reliance on imported medications.